Investments

We are short shares of HubSpot, Inc. (HUBS), an unprofitable SaaS company that, despite the recent downward re-rating of the tech sector, still trades at 20x forward revenue. HubSpot is not worth anything close to its current valuation. The company is a COVID beneficiary whose future growth will likely pale in…

We are short shares of Meta Materials, a $1 billion market cap company whose business is comprised of a whole lot of nothing: no real revenue, no promising technologies, undeveloped products, no track record of achievement. The company is a collection of disjointed and failed laboratory experiments designed, in our…

We are short shares of Camber Energy, Inc. Camber is a defunct oil producer that has failed to file financial statements with the SEC since September 2020, is in danger of having its stock delisted next month, and just fired its accounting firm in September. Its only real asset is a 73% stake in Viking Energy…

We are short shares of Virgin Galactic Holdings, Inc., often described as the only publicly traded space-tourism company. After going public in October 2019 by way of a merger with a “blank check” company, Virgin Galactic has seen its share price and trading volume soar. It’s become a retail darling, with day traders captivated…

We are short shares of Plug Power, a $40 billion provider of hydrogen fuel-cell solutions that’s set to generate a paltry $300 million in revenue in 2020 and trades at 40x its own aggressive revenue projection for 2024. The company’s stock has almost doubled in just the last few weeks, and has risen by 15x in the last year…

We are short shares of Fubo, a $6bn company that has seen its share price increase 4x following its October 7^th IPO on the NYSE. Remarkably, even after its recent retracement from truly nosebleed levels, Fubo still trades at valuations completely unmoored from reality: 14x 2021E sales, equivalent to $12,000 per current…

We are short shares of Tattooed Chef, a $1.2bn packaged-food company that trades at about 7.5x 2020 revenues despite extreme customer concentration and flagging retail sales. Having recently gone public through acquisition by Forum Merger II Corporation, a special purpose acquisition company (SPAC)…

We are short shares of AtriCure, a $1.9bn medical device company that manufactures and sells ablation equipment used in the surgical treatment of atrial fibrillation (AF). At about 7x forward revenues, AtriCure’s valuation implies that the company’s outlook is brighter than at any point in the last decade. But with…

We are short shares of Mirati Therapeutics, a $4.6bn clinical-stage biopharmaceutical company whose lead drug candidate, MRTX-849, is a small-molecule KRAS inhibitor (KRASi). The KRAS protein plays a critical role in cell proliferation and differentiation, and mutations of the gene that encode it are present in…

We are short shares of Match Group and IAC/InterActiveCorp, two companies trying to break apart before an FTC lawsuit that alleges a disturbing level of civil fraud and a parallel DOJ criminal investigation leads to the market dumping them both. Last September, the FTC sued…

We are short shares of Principia Biopharma, a company whose $2 billion valuation rests on a single obscure molecule known as Bruton’s tyrosine kinase (BTK). Named after a pediatrician who discovered an immunodeficiency later found to be caused by a defective mutant form of…

We are short shares of CareDx, a $1.7bn diagnostics company whose share price has increased by 30x over just the last two years and now trades at over 18x sales. The meteoric rise and generous valuation have come in the wake of excitement over the commercialization of AlloSure, a blood test intended to identify organ rejection in kidney transplant recipients. Transplant nephrologists have long used measures of kidney function to assess the probability of rejection, with a tissue biopsy providing a definitive diagnosis. To hear CareDx tell it, AlloSure is the…